SGMO Sangamo Therapeutics
- 0.560
- +0.159+39.55%
- 0.550
- -0.010-1.79%
Sangamo Therapeutics News
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(2.3%)
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Duraibabu Prathyusha
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Smith Karen L.
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Horn Margaret A
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Markels John
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Meyers James R
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director PARKER H STEWART
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hillan Kenneth J.
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Carey Robert
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Beers Courtney
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dubois-Stringfellow Nathalie
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Willoughby Scott B.
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pooler Amy
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Duraibabu Prathyusha
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Macrae Sandy
Sangamo Therapeutics | 10-Q: Quarterly report
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS
Sangamo Therapeutics | 8-K: Current report
Analysis
Price Target
No Data
